0harnessingno2019 08 09cool
Zylo 20logo

Zylö Therapeutics

Zylö's has developed and commercialized a platform technology that provides a diversified portfolio of solutions across multiple industries.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Greenville, SC, USA
  • Currency USD
  • Founded November 2017
  • Employees 7
  • Incorporation Type C-corp
  • Website zylotherapeutics.com

Company Summary

The Z-pod delivery system is versatile, affordable & 'next-generation, with countless applications' (source: a leading MD who heads the Nanodermatology Society)

Every firm competing in cannabis/cosmetics/skin care/pharma is desperate for innovation. Z-pods provide just that.

We have a diversified portfolio of signed partnerships; we have scaled up and are selling product; and we are determined to produce a 10X return for our investors.


  • 526cd4a3 1019 4f87 a6f0 08aaa79d04af
    CEO/Founder/Board Member

    CEO of Lpath, 2005-14, took from incubation at SDSU to NASDAQ listing, raised $90M equity, $50M non dilutive capital, partnered with Merck, Pfizer, J&J & Biogen. On DermTech Board (2012-2021), helping CEO grow from raw startup to Nasdaq listing and $1B+ market cap. EVP of WSIG 1994-04, managed portfolio of startups, incl. Endonetics (sold to Medtronic), Mpex (sold to Allergan), Vaxiion (in Ph.1). BA-UVA summa cum laude; MBA-Harvard (honors)

  • Fdf67df6 dcf0 40e8 8d44 a2e028ff86d5
    Vice President of Business Development

    Dr. Blankenship is an emergency MD w/ healthcare startup experience. Most recently, he was Chair of Emergency Services at a large health system. He previously served as Medical Director of Lucidity Direct, a start-up technology platform; did product dev. work at Bard; served as an Associate at the Lassonde New Venture Dev. Center, evaluating novel biotechnologies. Degrees: BA--UVA, MD--U of South Alabama, MBA--UNC Chapel Hill.

  • 3bcff8ce ea45 4193 907d 1e4da6bea189
    Chief Financial Officer

    Charles (a CPA) started at Bain & Company and Bain Capital. He was then CFO+CEO of an automotive foundry (1985-2015), which he grew from $4M to $50M before selling it to a P/E firm. He then became CFO+CEO of an equip. mfr., diversifying its product offering via a startup company that developed a breakthrough technology in oilfield pipe handling. Degrees: BS--W&L (summa cum laude); MBA-Harvard (Baker Scholar).

  • 4db96ec9 fdec 47f2 a719 bc957d02c7f3
    Director of Product Development

    Dr. Draganski completed his Ph.D. at Rutgers and then joined Dr. Joel Friedman's laboratory at Albert Einstein College of Medicine; there, he worked on the advancement of the lab's novel drug-delivery platform, becoming the primary inventor of the company’s Z-pod™ delivery platform.

  • 29f39129 9467 4d06 bdbf 9caa13dcffac
    Director of Manufacturing and Engineering

    Chris Mann joined Zylö 1/2020 w/ the aim of scaling up the Z-pod™ delivery technology. He's a veteran of another high-tech startup, Plextronics, as well as specialty materials maker Chase Corporation), a paint/coatings mfr Valspar & 3M. He has led scale-up efforts in multiple industries and has valuable experience in design, construction mgmt, and startup/operation of new facilities. Degrees: BS in Chemical Engineering/Chemistry--Penn State

  • Default avatar
    Michael Rabin
    Vice President (part time)

    For ~20 years, Mr. Rabin was lead producer at a boutique Investment Bank doing M&A of OTC/cosmetic brands.
    Previously with Goldman Sachs and a management consulting firm.
    BS economics-U. of Chicago; MBA-Harvard

  • 181abf9e 3d60 49d7 be54 c8dc92311696
    Vice President (part time)

    Dr. Burns has extensive experience in FDA-regulated mfg, R&D, BD, licensing, M&A, At Ferndale Pharma Group (1993-2020), he was President and COO; Ferndale makes and markets Rx and non-Rx dermatological products. Previously, he was CEOof Repromedix, specializing in male and female infertility diagnostics. He is also on the board of SciTech, which develops cancer drugs. Degrees: B.Sc. (Honors)--U of Reading; Ph.D. in Pharmacology--U. of Cambridge


  • Default avatar
    Adam Friedman MD
    Default avatar
    Joshua Nosanchuk MD
  • Default avatar
    Kelvin Davies PhD

Previous Investors